P
Piramal Pharma Ltd
NSE:PPLPHARMA
Piramal Pharma Ltd
NSE:PPLPHARMA
Price:
151.8
INR
-0.98%
Market Closed
Market Cap:
₹200.9B
Balance Sheet
Balance Sheet Decomposition
Piramal Pharma Ltd
Piramal Pharma Ltd
Balance Sheet Decomposition is not available for
Piramal Pharma Ltd
Piramal Pharma Ltd
Balance Sheet
Piramal Pharma Ltd
Piramal Pharma Ltd
Currency: INR
| Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
1 523
|
903
|
3 076
|
3 568
|
5 015
|
|
| Cash |
56
|
56
|
1 120
|
3 568
|
3 690
|
|
| Cash Equivalents |
1 467
|
847
|
1 956
|
0
|
1 325
|
|
| Short-Term Investments |
1 003
|
645
|
4 309
|
1 447
|
196
|
|
| Total Receivables |
8 504
|
9 950
|
21 393
|
24 620
|
27 184
|
|
| Accounts Receivables |
8 398
|
9 477
|
18 166
|
21 356
|
23 768
|
|
| Other Receivables |
106
|
473
|
3 228
|
3 265
|
3 415
|
|
| Inventory |
4 207
|
4 813
|
18 127
|
22 964
|
24 535
|
|
| Other Current Assets |
2 438
|
3 275
|
2 570
|
2 045
|
2 366
|
|
| Total Current Assets |
17 675
|
19 585
|
48 355
|
54 645
|
57 970
|
|
| PP&E Net |
13 846
|
14 652
|
44 415
|
48 160
|
50 235
|
|
| PP&E Gross |
13 846
|
14 652
|
44 415
|
48 160
|
50 235
|
|
| Accumulated Depreciation |
4 374
|
5 144
|
19 489
|
23 636
|
28 092
|
|
| Intangible Assets |
3 632
|
3 488
|
33 382
|
31 672
|
29 386
|
|
| Goodwill |
0
|
0
|
11 075
|
11 226
|
11 482
|
|
| Note Receivable |
6 138
|
7 917
|
12
|
940
|
854
|
|
| Long-Term Investments |
16 023
|
26 114
|
2 119
|
2 403
|
2 711
|
|
| Other Long-Term Assets |
253
|
327
|
5 868
|
4 073
|
4 138
|
|
| Other Assets |
0
|
0
|
11 075
|
11 226
|
11 482
|
|
| Total Assets |
57 567
N/A
|
72 083
+25%
|
145 226
+101%
|
153 118
+5%
|
156 776
+2%
|
|
| Liabilities | ||||||
| Accounts Payable |
5 841
|
6 152
|
11 927
|
15 384
|
15 338
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1 594
|
2 102
|
|
| Short-Term Debt |
0
|
0
|
13 023
|
11 714
|
9 953
|
|
| Current Portion of Long-Term Debt |
1 669
|
6 562
|
8 493
|
9 370
|
5 479
|
|
| Other Current Liabilities |
7 207
|
2 457
|
4 987
|
5 631
|
4 791
|
|
| Total Current Liabilities |
14 717
|
15 171
|
38 431
|
43 693
|
37 663
|
|
| Long-Term Debt |
74
|
4 552
|
34 855
|
26 017
|
33 132
|
|
| Deferred Income Tax |
1 704
|
1 575
|
2 193
|
2 292
|
2 484
|
|
| Other Liabilities |
66
|
111
|
2 012
|
2 002
|
2 243
|
|
| Total Liabilities |
16 561
N/A
|
21 410
+29%
|
77 491
+262%
|
74 004
-4%
|
75 521
+2%
|
|
| Equity | ||||||
| Common Stock |
9 946
|
11 859
|
11 933
|
13 230
|
13 244
|
|
| Retained Earnings |
0
|
0
|
13 631
|
14 048
|
15 192
|
|
| Additional Paid In Capital |
0
|
0
|
38 187
|
47 249
|
47 372
|
|
| Other Equity |
31 060
|
38 814
|
3 984
|
4 587
|
5 447
|
|
| Total Equity |
41 006
N/A
|
50 673
+24%
|
67 735
+34%
|
79 114
+17%
|
81 255
+3%
|
|
| Total Liabilities & Equity |
57 567
N/A
|
72 083
+25%
|
145 226
+101%
|
153 118
+5%
|
156 776
+2%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
1 186
|
1 186
|
1 217
|
1 323
|
1 324
|
|
Switch to:
Switch to:
See Also
Discover More
